Disease Site Breast Disease You have free access to this content Effectiveness of radiation for prevention of mastectomy in older breast cancer patients treated with conservative surgery (pages 4642–4651)
Jeffrey M. Albert, I-Wen Pan, Ya-Chen Tina Shih, Jing Jiang, Thomas A. Buchholz, Sharon H. Giordano and Benjamin D. Smith
Version of Record online: 13 AUG 2012 | DOI: 10.1002/cncr.27457
Outside of a clinical trial, the receipt of radiation therapy after conservative surgery is associated with a greater likelihood of long-term breast preservation for most women ages 70 to 79 years with early breast cancer, and this benefit should be considered by patients and physicians when evaluating local treatment choices. However, radiation therapy does not appear to be beneficial for the subset of women ages 75 to 79 years with pathologic lymph node-negative disease who do not have high-grade tumors.
You have free access to this content Incidence of brain metastases as a first site of recurrence among women with triple receptor–negative breast cancer (pages 4652–4659)
Shaheenah Dawood, Xiudong Lei, Jennifer K. Litton, Thomas A. Buchholz, Gabriel N. Hortobagyi and Ana M. Gonzalez-Angulo
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27434
Patients with nonmetastatic triple receptor–negative (negative for estrogen receptor, progesterone receptor, and HER2/neu) breast cancer have a high early incidence of developing brain metastases as a first site of recurrence, which is associated with subsequent poor survival. Patients with stage III triple receptor–negative breast cancer in particular would be an ideal cohort in which to research preventive strategies.
You have free access to this content Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer (pages 4660–4669)
Maria T. Baquero, Jason A. Hanna, Veronique Neumeister, Huan Cheng, Annette M. Molinaro, Lyndsay N. Harris and David L. Rimm
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27453
Modulation of microtubule stabilization is associated with outcome. Increased expression of the stabilizing protein microtubule-associated protein tau or decreased expression of the destabilizing protein stathmin is associated with better outcome in breast cancer.
Gastrointestinal Disease You have free access to this content Identification of candidate genes carrying polymorphisms associated with the risk of colorectal cancer by analyzing the colorectal mutome and microRNAome (pages 4670–4680)
Debora Landi, Federica Gemignani, Barbara Pardini, Alessio Naccarati, Sonia Garritano, Pavel Vodicka, Ludmila Vodickova, Federico Canzian, Jan Novotny, Roberto Barale and Stefano Landi
Version of Record online: 26 JAN 2012 | DOI: 10.1002/cncr.27435
New loci of susceptibility to sporadic colorectal cancer are reported, and we also showed how to narrow the selection of genetic markers in order to perform association studies on highly relevant single-nucleotide polymorphisms.
You have free access to this content The functional cytotoxic T lymphocyte–associated Protein 4 49G-to-A genetic variant and risk of pancreatic cancer (pages 4681–4686)
Ming Yang, Tong Sun, Yifeng Zhou, Li Wang, Li Liu, Xiaojiao Zhang, Xiaohu Tang, Mo Zhou, Pengqun Kuang, Wen Tan, Hui Li, Qipeng Yuan and Dianke Yu
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27455
This study found that the functional
cytotoxic T lymphocyte–associated antigen 4 ( CTLA-4) 49G-to-A single-nucleotide polymorphism is significantly associated with increased risk of pancreatic cancer, alone and in a multiplicative gene–age, gene–smoking, or gene–drinking interaction manner. Therefore, this functional genetic variation may have tremendous implications for pancreatic cancer and be used for identifying individuals at high risk for developing pancreatic cancer. You have free access to this content Clinical implication of an insufficient number of examined lymph nodes after curative resection for gastric cancer (pages 4687–4693)
Taeil Son, Woo Jin Hyung, Joong Ho Lee, Yoo Min Kim, Hyoung-Il Kim, Ji Yeong An, Jae-Ho Cheong and Sung Hoon Noh
Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27426
Lymph node-negative cancers in which ≤15 lymph nodes are examined, classified as N0 in the new TNM staging system, cannot adequately predict patient survival after curative gastrectomy, especially in patients with early stage gastric cancer.
Head and Neck Disease You have free access to this content Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer : Final results of a randomized, double-blind, placebo-controlled, phase 3 study (pages 4694–4705)
Susan Urba, Carla M. L. van Herpen, Tarini Prasad Sahoo, Dong M. Shin, Lisa Licitra, Klara Mezei, Christoph Reuter, Ricardo Hitt, Francesca Russo, Shao-Chun Chang, Anwar M. Hossain, Bente Frimodt-Moller, Andrew Koustenis and Ruey-Long Hong
Version of Record online: 20 MAR 2012 | DOI: 10.1002/cncr.27449
In a double-blind, placebo-controlled, phase 3 trial, patients with recurrent or metastatic squamous cell carcinoma of the head and neck are randomized to pemetrexed plus cisplatin or placebo plus cisplatin to assess overall survival and secondary endpoints. Pemetrexed-cisplatin does not significantly improve survival for the intention-to-treat population. However, in a preplanned subgroup analysis, pemetrexed-cisplatin leads to longer overall survival and progression-free survival for patients with performance status 0 or 1 and patients with oropharyngeal cancers.
Hematologic Malignancies You have free access to this content A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma (pages 4706–4714)
Avichai Shimoni, Irit Avivi, Jacob M. Rowe, Moshe Yeshurun, Itai Levi, Reuven Or, Paulina Patachenko, Abraham Avigdor, Tzila Zwas and Arnon Nagler
Version of Record online: 17 JAN 2012 | DOI: 10.1002/cncr.27418
Ibritumomab tiuxetan (Zevalin) combined with BEAM high-dose chemotherapy is safe and possibly more effective than BEAM alone as a conditioning regimen for autologous stem cell transplantation in the era of rituximab-containing chemotherapy regimens.
You have free access to this content Burkitt post-transplantation lymphoma in adult solid organ transplant recipients : Sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients (pages 4715–4724)
Heiner Zimmermann, Petra Reinke, Ruth Neuhaus, Hans Lehmkuhl, Stephan Oertel, Johannes Atta, Manfred Planker, Barbara Gärtner, Dido Lenze, Ioannis Anagnostopoulos, Hanno Riess and Ralf U. Trappe
Version of Record online: 5 MAR 2012 | DOI: 10.1002/cncr.27482
Burkitt lymphoma post-transplantation lymphoproliferative disorder (Burkitt-PTLD) is a rare form of adult PTLD with clinical and histologic features similar to Burkitt lymphoma in the nontransplantation population. In the largest adult case series to date in this disease entity, sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or R-CHOP is a safe and effective treatment for this aggressive tumor.
Hepatobiliary Disease You have free access to this content Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus (pages 4725–4736)
Zhen-Wei Peng, Rong-Ping Guo, Yao-Jun Zhang, Xiao-Jun Lin, Min-Shan Chen and Wan Y. Lau
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.26561
Hepatic resection (HR) is a safe treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). Compared with transcatheter arterial chemoembolization (TACE), HR provided survival benefits for patients with HCC with PVTT.
You have free access to this content The impact of portal vein resection on outcomes for hilar cholangiocarcinoma : A multi-institutional analysis of 305 cases (pages 4737–4747)
Mechteld C. de Jong, Hugo Marques, Bryan M. Clary, Todd W. Bauer, J. Wallis Marsh, Dario Ribero, Pietro Majno, Ioannis Hatzaras, Dustin M. Walters, Andrew S. Barbas, Raquel Mega, Richard D. Schulick, Michael A. Choti, David A. Geller, Eduardo Barroso, Gilles Mentha, Lorenzo Capussotti and Timothy M. Pawlik
Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27492
The role of portal vein resection for hilar cholangiocarcinoma remains controversial. In this study, among 305 patients who undergo resection of hilar cholangiocarcinoma, 51 (16.7%) undergo concurrent portal vein resection. Portal vein resection is associated with increased perioperative mortality but long-term outcomes similar to those achieved by patients who do not undergo portal vein resection.
Lung Disease You have free access to this content Primary pulmonary lymphoepithelioma-like carcinoma : Fifty-two patients with long-term follow-up (pages 4748–4758)
Ying Liang, Liang Wang, Yujia Zhu, Yongbin Lin, Hui Liu, Huilan Rao, Guangchuan Xu and Tiehua Rong
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27452
This study of the largest cohort to date of patients with pulmonary lymphoepithelioma-like carcinoma confirms the better prognosis and distinct features and indicates that surgery is the optimal therapy for most patients.
Neuro-Oncology You have free access to this content Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma (pages 4759–4767)
David A. Reardon, Annick Desjardins, James J. Vredenburgh, James E. Herndon II, April Coan, Sridharan Gururangan, Katherine B. Peters, Roger McLendon, Sith Sathornsumetee, Jeremy N. Rich, Eric S. Lipp, Dorothea Janney and Henry S. Friedman
Version of Record online: 27 FEB 2012 | DOI: 10.1002/cncr.26541
Platelet-derived growth factor receptor (PDGFR) signaling is important in the biology of low-grade gliomas (LGG). In our phase II study, imatinib as a PDGFR inhibitor was well tolerated but had negligible antitumor activity when combined with hydroxyurea among adult patients with recurrent/progressive LGG.
Skin You have free access to this content Nonsteroidal anti-inflammatory drugs and the risk of skin cancer : A population-based case-control study (pages 4768–4776)
Sigrun Alba Johannesdottir, Ellen T. Chang, Frank Mehnert, Morten Schmidt, Anne Braae Olesen and Henrik Toft Sørensen
Version of Record online: 29 MAY 2012 | DOI: 10.1002/cncr.27406
In this population-based case-control study, the use of nonsteroidal anti-inflammatory drugs (aspirin, other nonselective nonsteroidal anti-inflammatory drugs, or cyclooxygenase-2 inhibitors) is associated with decreased skin cancer risk. The reduction in risk increases with greater duration and intensity of use.
Discipline Clinical Trials You have free access to this content Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer : A Prostate Cancer Clinical Trials Consortium trial (pages 4777–4784)
Robert W. Ross, Matthew D. Galsky, Phil Febbo, Marc Barry, Jerome P. Richie, Wanling Xie, Fiona M. Fennessy, Rupal S. Bhatt, Julia Hayes, Toni K. Choueiri, Clare M. Tempany, Philip W. Kantoff, Mary E. Taplin and William K. Oh
Version of Record online: 26 JAN 2012 | DOI: 10.1002/cncr.27416
Neoadjuvant docetaxel combined with bevacizumab is safe and results in reductions in both tumor volume and serum prostate-specific antigen in men with high-risk localized prostate cancer. The role of neoadjuvant chemotherapy in prostate cancer, and perioperative antiangiogenic therapy in general, requires further elucidation through ongoing and planned trials.
You have free access to this content Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients : A prospective, randomized, placebo-controlled phase 2 study (pages 4785–4794)
Yuichiro Hiura, Shuji Takiguchi, Kazuyoshi Yamamoto, Tsuyoshi Takahashi, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Hiroshi Miyata, Yoshiyuki Fujiwara, Masaki Mori, Kenji Kangawa and Yuichiro Doki
Version of Record online: 26 JAN 2012 | DOI: 10.1002/cncr.27430
To the authors' knowledge, this is the first report on the usefulness of ghrelin during cisplatin-based chemotherapy in humans. Administration of synthetic ghrelin during cisplatin-based neoadjuvant chemotherapy successfully increases appetite and increases food intake by approximately 20%.
You have free access to this content A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors (pages 4795–4800)
Diane L. Reidy-Lagunes, Efsevia Vakiani, Michal F. Segal, Ellen M. Hollywood, Laura H. Tang, David B. Solit, M. Catherine Pietanza, Marinela Capanu and Leonard B. Saltz
Version of Record online: 21 MAR 2012 | DOI: 10.1002/cncr.27459
Well-differentiated neuroendocrine tumors (NETs) respond to somatostatin analogs and mammalian target of rapamycin inhibition, and preclinical studies suggest that these agents exhibit their antitumor activity through the inhibition of upstream type-1 insulin-like growth factor (IGF-1)-dependent signaling. In this phase 2 study, the authors use a humanized IGF-1 receptor monoclonal antibody (MK-0646) as a therapeutic approach in well-differentiated NETs (carcinoid tumors and pancreatic NETs), but they fail to demonstrate clinical benefit.
You have free access to this content Patient advocates' role in clinical trials : Perspectives from Cancer and Leukemia Group B investigators and advocates (pages 4801–4805)
Mira L. Katz, Laura E. Archer, Jeffrey M. Peppercorn, Sandra Kereakoglow, Deborah E. Collyar, Harold J. Burstein, Richard L. Schilsky and Ann H. Partridge
Version of Record online: 5 MAR 2012 | DOI: 10.1002/cncr.27485
The majority of Cancer and Leukemia Group B (CALGB) patient advocates and investigators perceive benefits from patient advocate involvement in the clinical trials process. Strategies to improve advocate-investigator communication to enhance the role of patient advocates in the clinical trial process are warranted.
You have free access to this content Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971 : A report from the Children's Oncology Group (pages 4806–4814)
April D. Sorrell, Todd A. Alonzo, Joanne M. Hilden, Robert B. Gerbing, Thomas W. Loew, Lois Hathaway, Dorothy Barnard, Jeffrey W. Taub, Yaddanapudi Ravindranath, Franklin O. Smith, Robert J. Arceci, William G. Woods and Alan S. Gamis
Version of Record online: 5 MAR 2012 | DOI: 10.1002/cncr.27484
Children's Oncology Group trial A2971 (COG A2971), the first phase 3 trial designed to uniformly treat myeloid leukemia in North American children with Down syndrome, eliminates 2 induction drugs and 3 months of maintenance from the standard-timing dexamethasone, cytarabine, 6-thioguanine, etoposide, and rubidomycin/daunomycin (DCTER) regimen that was used in Children's Cancer Group trial 2891. COG A2971 reduces the chemotherapy dose and maintains survival in children who have myeloid leukemia associated with Down syndrome.
Complementary Medicine You have free access to this content Use of complementary medications among older adults with cancer (pages 4815–4823)
Ronald J. Maggiore, Cary P. Gross, Kayo Togawa, William P. Tew, Supriya G. Mohile, Cynthia Owusu, Heidi D. Klepin, Stuart M. Lichtman, Ajeet Gajra, Rupal Ramani, Vani Katheria, Shira M. Klapper, Kurt Hansen, Arti Hurria and on behalf of the Cancer and Aging Research Group
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27427
The use of herbal/complementary medications is observed in up to 17% of older adults with cancer who are receiving chemotherapy. The types of these agents used in this population may be distinct from those encountered among older adults in general.
Disparities Research You have free access to this content Gender representation of cancer patients in medical treatment and psychosocial survivorship research : Changes over three decades (pages 4824–4832)
Michael A. Hoyt and Lisa R. Rubin
Version of Record online: 31 JAN 2012 | DOI: 10.1002/cncr.27432
This paper reviews gender representation in biomedical treatment and psychosocial studies published in a single year, using an established methodology to directly compare current findings with prior research. Results indicate that women remain under-represented in biomedical treatment studies of sex-nonspecific cancers; men are no longer under-represented in psychosocial studies overall, and their inclusion in studies of feelings/emotions and social relationships has increased, whereas women are better represented in studies of physical/functional ability than in prior years.
You have free access to this content The impact of insurance status on outcomes after surgery for spinal metastases (pages 4833–4841)
Hormuzdiyar H. Dasenbrock, Jean-Paul Wolinsky, Daniel M. Sciubba, Timothy F. Witham, Ziya L. Gokaslan and Ali Bydon
Version of Record online: 31 JAN 2012 | DOI: 10.1002/cncr.27388
In this study, 2157 patients from across the United States who underwent surgery for spinal metastases were examined to investigate the impact of payer status on postoperative outcomes. Although rates of in-hospital mortality were significantly higher for Medicaid recipients and those without insurance compared with patients with private insurance, these differences were largely attributable to a higher acuity of presentation for care.
You have free access to this content Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States : Report from the National LymphoCare Study (pages 4842–4850)
Chadi Nabhan, Michelle Byrtek, Michael D. Taylor, Jonathan W. Friedberg, James R. Cerhan, John D. Hainsworth, Thomas P. Miller, Jamie Hirata, Brian K. Link and Christopher R. Flowers
Version of Record online: 20 MAR 2012 | DOI: 10.1002/cncr.27513
The authors demonstrate for the first time that racial disparities in follicular lymphoma presentation and disease characteristics exist in the United States between white, African American, and Hispanic patients. Furthermore, the management of this disease varies among these ethnic groups, likely contributing to the observed differences in outcomes.
You have free access to this content Patient navigation for breast and colorectal cancer in 3 community hospital settings : An economic evaluation (pages 4851–4859)
Elisabeth A. Donaldson, David R. Holtgrave, Renea A. Duffin, Frances Feltner, William Funderburk and Harold P. Freeman
Version of Record online: 5 MAR 2012 | DOI: 10.1002/cncr.27487
Patient navigation targets the medically underserved with the objective of reducing the time interval between an abnormal cancer finding, diagnostic resolution, and treatment initiation. Implementing breast or colorectal cancer patient navigation in community hospital settings in which low-income populations are served could be a cost-effective addition to standard cancer care in the United States.
Epidemiology You have free access to this content Fat or fit: The joint effects of physical activity, weight gain, and body size on breast cancer risk (pages 4860–4868)
Lauren E. McCullough, Sybil M. Eng, Patrick T. Bradshaw, Rebecca J. Cleveland, Susan L. Teitelbaum, Alfred I. Neugut and Marilie D. Gammon
Version of Record online: 25 JUN 2012 | DOI: 10.1002/cncr.27433
Exercise at any intensity level during the reproductive and postmenopausal years has the greatest benefit for reducing breast cancer risk. Substantive postmenopausal weight gain may eliminate the benefits of regular activity.
You have free access to this content Increased risk of histologically defined cancer subtypes in human immunodeficiency virus–infected individuals : Clues for possible immunosuppression-related or infectious etiology (pages 4869–4876)
Meredith S. Shiels and Eric A. Engels
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27454
We assessed the risk of histologically defined cancers in people with acquired immunodeficiency syndrome, relative to the general population. A potential etiologic role of immunosuppression or infection may be indicated for malignancies that occur in excess among individuals infected with human immunodeficiency virus.
Medical Oncology You have free access to this content Correlation of drug-induced apoptosis assay results with oncologist treatment decisions and patient response and survival (pages 4877–4883)
Linda D. Bosserman, Swapnil P. Rajurkar, Karl Rogers, Dirk C. Davidson, Michael Chernick, Allan Hallquist, Debbee Malouf and Cary A. Presant
Version of Record online: 21 FEB 2012 | DOI: 10.1002/cncr.27444
After oncologists receive MiCK assay results, 64% use the assay to help decide on a treatment plan. Patients whose physician uses the MiCK assay to choose treatment have higher response rates, longer relapse-free interval, and longer overall survival.
Pediatric Oncology You have free access to this content Health status of adolescent and young adult cancer survivors (pages 4884–4891)
Eric Tai, Natasha Buchanan, Julie Townsend, Temeika Fairley, Angela Moore and Lisa C. Richardson
Version of Record online: 11 JUN 2012 | DOI: 10.1002/cncr.27445
Adolescent and young adult (AYA) cancer survivors commonly report adverse behavioral, medical, and health care access characteristics, which may lead to poor long-term medical and psychosocial outcomes. Increased adherence to established follow-up guidelines may lead to improved health among AYA cancer survivors.
You have free access to this content Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults : Preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG (pages 4892–4900)
Martina Buehrlen, Christian Michel Zwaan, Bernd Granzen, Lisa Lassay, Peter Deutz, Peter Vorwerk, Gundula Staatz, Günther Gademann, Hans Christiansen, Foppe Oldenburger, Miriam Tamm and Rolf Mertens
Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27395
The authors report results from a prospective multicenter study of treatment for children with nasopharyngeal carcinoma. Special focus is paid to diagnostic imaging and interferon beta maintenance treatment.
Radiation Oncology You have free access to this content Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor/pigmented villonodular synovitis with radiotherapy and surgery (pages 4901–4909)
Anthony M. Griffin, Peter C. Ferguson, Charles N. Catton, Peter W. M. Chung, Lawrence M. White, Jay S. Wunder, Robert S. Bell and Brian O'Sullivan
Version of Record online: 26 JAN 2012 | DOI: 10.1002/cncr.26529
For those patients with extensive or multiple local relapses of diffuse tenosynovial giant cell tumor or those for whom surgery alone would result in a large burden of residual disease or major functional loss, the addition of moderate dose adjuvant radiotherapy after surgical excision is effective in providing excellent local control while maintaining good function with low treatment-related morbidity.